Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica Banterla, Elena Bresin, Claudio Tripodo, Serena Bettoni, Roberta Donadelli, Elisabetta Valoti, Francesco Tedesco, Alessandro Amore, Rosanna Coppo, Piero Ruggenenti, Eliana Gotti, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endothelial cells (HMEC-1). In adenosine 5'-diphosphate-activated HMEC-1, also sera from 84% and 100% of patients in remission, and from all unaffected mutation carriers, induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3 glomerulopathies/immune complex-associated membranoproliferative glomerulonephritis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even preceded remission, and guided drug dosing and timing. These results point to efficient complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial deposits might help monitor eculizumab effectiveness, avoid drug overexposure, and save money considering the extremely high cost of the drug.

Original languageEnglish
Pages (from-to)1715-1726
Number of pages12
JournalBlood
Volume124
Issue number11
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.'. Together they form a unique fingerprint.

  • Cite this

    Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., Tedesco, F., Amore, A., Coppo, R., Ruggenenti, P., Gotti, E., & Remuzzi, G. (2014). Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 124(11), 1715-1726. https://doi.org/10.1182/blood-2014-02-558296